U.S. Based Medicinova Aims To Boost Efficiency In Japanese Drug Development
This article was originally published in PharmAsia News
Executive Summary
California-based pharmaceutical venture company Medicinova plans to buy preclinical drug candidates in Japan that have been cleared for the clinic, and conduct more efficient clinical trials in Europe and the U.S., Medicinova President Yuichi Iwaki said in an interview in Mainichi News. Medicinova will then sell the products after the trials. Currently, Medicinova is developing 10 drugs, including Kissei's bronchitis and acute asthma candidate MN-221 and Kyorin's multiple sclerosis treatment MN-166. (Click for more-Japanese language
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.